PMDA drug package insert

オンボー皮下注100mgオートインジェクター

PMDA Prescription drug · 日本イーライリリー株式会社 · package insert Apr 16, 2026

Key facts

Brand names オンボー皮下注100mgオートインジェクター, オンボー皮下注200mgオートインジェクター, オンボー皮下注100mgシリンジ, オンボー皮下注200mgシリンジ
Nonproprietary names ミリキズマブ(遺伝子組換え)
Companies 製造販売元/日本イーライリリー株式会社, 販売/持田製薬株式会社
Product type Prescription drug
Therapeutic category ヒト化抗ヒトIL-23p19モノクローナル抗体製剤
Therapeutic category codes 87239
YJ codes 2399407G2020, 2399407G4023, 2399407G1024, 2399407G3027
Approval numbers 30500AMX00119, 30700AMX00067, 30500AMX00120, 30700AMX00068
Package insert edition 第7版
Package insert date Apr 16, 2026
PMDA document key 530471_2399407G1024_1
PMDA company code 530471

At a glance

  • 1–9 Package insert revisions
  • 10–99 Related PMDA documents
  • None Safety communications
  • Yes PMDA review report published
  • Yes Risk management plan (RMP)

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMDA approved drugs and package inserts (Japan)

Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.

Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date:

Browse all PMDA approved drugs and package inserts (Japan)